What's Happening
E-Bulletin

You are here

Home > What's Happening > E-Bulletin > Issue No 42 > Drug & Patient Safety Updates
  • Consumers Warned About Tainted Weight Loss Pills
  •  Acute Kidney Injury Risks for Oral Sodium Phosphate Products

 

• Consumers Warned About Tainted Weight Loss Pills
The US FDA is alerting consumers not to purchase or consume more than 25 different products marketed for weight loss because they contain undeclared, active pharmaceutical ingredients that may put consumers’ health at risk. Some of which might find their way here on our retails shelves or even through internet orders. In early Dec 2008, HSA also issued similar alert on 2 slimming health products (Relacore & Lami). Labs results revealed that they were adulterated with sibutramine after 3 ADRs  implicating both products were investigated.
Like in the US, many such products are not regulated in Singapore for the quality, safety and efficacy like other drugs. Therefore, as trained healthcare professionals, pharmacists must play be more vigilant and responsible in advising patients/public about many of such slimming products on the basis of proven and sound scientific evidence. For full details of the American brands affected, please read full release at: http://www.fda.gov/bbs/topics/NEWS/2008/NEW01933.html

 

 

 

• Acute Kidney Injury Risks for Oral Sodium Phosphate Products
The US FDA announced that it will add a Boxed Warning to the prescription oral sodium phosphate products Visicol and OsmoPrep to warn consumers about the risk of acute phosphate nephropathy (a type of acute kidney injury). Patients routinely take OSP products to cleanse the bowel before a colonoscopy (colon examination) and other medical procedures.
The FDA has also directed the manufacturer of these products to develop a risk evaluation and mitigation strategy (REMS), distribute a Medication Guide to alert patients to the risk of acute kidney injury associated with the use of these products, and to conduct a postmarketing clinical trial to further assess the risk of acute kidney injury with the use of these products.
For full alert, please visit: http://www.fda.gov/bbs/topics/NEWS/2008/NEW01923.html

 

 

 

 

 

**********

Back to Issue No 42